Processing...
Clinical Trials for Small Cell Lung Cancer
Search
Search
There are 488 active trials for advanced/metastatic small cell lung cancer.
Click on a trial to see more information.
488 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Patients with advanced solid tumors after standard therapy has failed or is unsuitable receive intravenous BNT317, an investigational bispecific antibody targeting PD-1 and CD39, in dose escalation. Expansion cohorts evaluate BNT317 alone in previously treated clear-cell renal cell carcinoma and with standard-of-care chemotherapy in previously treated HER2-negative gastric or gastroesophageal-junction cancer and non-small-cell lung cancer without actionable alterations.
ClinicalTrials.gov ID: NCT06750185
TrialFetch AI summary: Adults with advanced solid tumors and no curative option after standard therapy receive intravenous STX-003 alone or with pembrolizumab; expansion cohorts focus on previously treated PD-L1-positive NSCLC and cutaneous melanoma. STX-003 is a lipid nanoparticle–delivered, self-replicating mRNA therapy designed to drive tumor-selective IL-12 expression and stimulate antitumor immunity.
ClinicalTrials.gov ID: NCT07751042
TrialFetch AI summary: Adults with unresectable or metastatic ALK-positive NSCLC that has progressed after prior systemic therapy, including at least one ALK inhibitor other than crizotinib alone, receive oral AQUA07 alone or with lorlatinib. AQUA07 is an investigational allosteric ALK inhibitor that binds outside the ATP-binding pocket; lorlatinib is an ATP-competitive ALK/ROS1 inhibitor.
ClinicalTrials.gov ID: NCT07617337
TrialFetch AI summary: Adults with progressive, advanced or metastatic DLL3-positive relapsed/refractory small-cell lung cancer or select high-grade neuroendocrine carcinomas after at least one standard systemic therapy receive ML261, an autologous DLL3-targeted CAR T-cell therapy engineered with a CARD11–PIK3R3 fusion protein to enhance T-cell signaling and persistence.
ClinicalTrials.gov ID: NCT07488923
TrialFetch AI summary: Adults with relapsed, refractory, or previously treated DLL3-positive small-cell lung cancer or other advanced neuroendocrine tumors receive lymphodepleting chemotherapy followed by autologous DLL3-targeted CAR T cells engineered to secrete IL-18 and enhance costimulatory signaling.
ClinicalTrials.gov ID: NCT07783477
TrialFetch AI summary: Adults with unresectable locally advanced or metastatic EGFR-mutant NSCLC that has progressed on a third-generation EGFR inhibitor receive oral H002, an investigational fourth-generation EGFR tyrosine kinase inhibitor designed to target activating EGFR mutations and resistance mutations including C797S. The expansion cohort requires centrally confirmed EGFR C797S.
ClinicalTrials.gov ID: NCT05519293
TrialFetch AI summary: Adults with advanced or recurrent solid tumors after standard therapy receive intravenous AG01, an investigational antibody targeting progranulin/GP88 to inhibit tumor growth and survival signaling. Expansion cohorts enroll previously treated patients with triple-negative or hormone-resistant breast cancer, non-small-cell lung cancer, or mesothelioma, generally requiring tumor GP88 expression.
ClinicalTrials.gov ID: NCT05627960
TrialFetch AI summary: Adults with previously treated advanced or metastatic solid tumors, ECOG 0–1, measurable disease, and a biopsiable tumor receive intravenous or subcutaneous ST-067, alone, after obinutuzumab pretreatment, or with pembrolizumab. ST-067 is an engineered IL-18 that activates the IL-18 receptor while resisting neutralization by IL-18 binding protein; expansion cohorts focus on melanoma, renal cell, triple-negative breast, non-small cell lung, head and neck squamous cell, and MSI-high cancers.
ClinicalTrials.gov ID: NCT04787042
TrialFetch AI summary: Adults with ECOG 0–1 and advanced selected solid tumors who have exhausted or are ineligible for standard treatment receive oral TT-10 (PORT-6), an adenosine A2A receptor antagonist, oral TT-4 (PORT-7), an adenosine A2B receptor antagonist, or both. Eligible tumor types vary by cohort and include RCC, CRPC, NSCLC, head and neck, colorectal, endometrial, and ovarian cancers.
ClinicalTrials.gov ID: NCT04969315
TrialFetch AI summary: Adults with previously treated, recurrent or metastatic HER2-positive solid tumors and ECOG performance status 0–1 receive XMT-2056 monotherapy, a HER2-targeted antibody–drug conjugate that delivers a STING agonist to stimulate innate immune signaling. Untreated or progressive CNS metastases and prior STING-directed therapy are excluded.
ClinicalTrials.gov ID: NCT05514717